I attended the Health Canada meeting in the fall around drug safety and effectiveness, and it's produced a report. I think it talks about the need for a system after the drugs come on the market, to monitor it. It had numerous stakeholders there, people from industry, a number of people from patient groups, and so on.
There were briefings on the national pharmaceutical strategy across the country. There was one in Atlantic Canada, in Newfoundland, that I was invited to attend, but I was unable to attend.
The co-chairs of the part that deals with drug safety and effectiveness have been trying to work with academics, and they have a number of consultation papers coming out. I haven't seen them, but I know they have been working hard in that area.